Metabolon has partnered with the Scottish Early Rheumatoid Arthritis (SERA) Study to identify possible rheumatoid arthritis biomarkers.
The partnership aims to discover circulating small molecules that could be used to predict a patient's risk of developing rheumatoid arthritis, track the progression of the illness, and monitor their response to treatment. Using Metabolon's extensive library of small molecules in combination with SERA's well-curated patient cohort, the initiative plans to incorporate metabolomic data with clinical and genomic information.
The overall goal is to understand better the underlying molecular mechanisms of rheumatoid arthritis, which could inform improved diagnostic approaches and treatment strategies.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.